

Author(s): David Ginsburg, M.D., 2012

License: Unless otherwise noted, this material is made available under the terms of the **Creative Commons Attribution–Non-commercial–Share Alike 3.0 License:**
<http://creativecommons.org/licenses/by-nc-sa/3.0/>

We have reviewed this material in accordance with U.S. Copyright Law **and have tried to maximize your ability to use, share, and adapt it.** The citation key on the following slide provides information about how you may share and adapt this material.

Copyright holders of content included in this material should contact open.michigan@umich.edu with any questions, corrections, or clarification regarding the use of content.

For more information about **how to cite** these materials visit <http://open.umich.edu/education/about/terms-of-use>.

Any **medical information** in this material is intended to inform and educate and is **not a tool for self-diagnosis** or a replacement for medical evaluation, advice, diagnosis or treatment by a healthcare professional. Please speak to your physician if you have questions about your medical condition.

Viewer discretion is advised: Some medical content is graphic and may not be suitable for all viewers.

Attribution Key

for more information see: <http://open.umich.edu/wiki/AttributionPolicy>

Use + Share + Adapt

{ Content the copyright holder, author, or law permits you to use, share and adapt. }



Public Domain – Government: Works that are produced by the U.S. Government. (17 USC § 105)



Public Domain – Expired: Works that are no longer protected due to an expired copyright term.



Public Domain – Self Dedicated: Works that a copyright holder has dedicated to the public domain.



Creative Commons – Zero Waiver



Creative Commons – Attribution License



Creative Commons – Attribution Share Alike License



Creative Commons – Attribution Noncommercial License



Creative Commons – Attribution Noncommercial Share Alike License



GNU – Free Documentation License

Make Your Own Assessment

{ Content Open.Michigan believes can be used, shared, and adapted because it is ineligible for copyright. }



Public Domain – Ineligible: Works that are ineligible for copyright protection in the U.S. (17 USC § 102(b)) *laws in your jurisdiction may differ

{ Content Open.Michigan has used under a Fair Use determination. }



Fair Use: Use of works that is determined to be Fair consistent with the U.S. Copyright Act. (17 USC § 107) *laws in your jurisdiction may differ

Our determination **DOES NOT** mean that all uses of this 3rd-party content are Fair Uses and we **DO NOT** guarantee that your use of the content is Fair.

To use this content you should **do your own independent analysis** to determine whether or not your use will be Fair.

The Human Genome I

M1 Patients and Populations

David Ginsburg, MD

Fall 2012



Relationships with Industry

UMMS faculty often interact with pharmaceutical, device, and biotechnology companies to improve patient care, and develop new therapies. UMMS faculty disclose these relationships in order to promote an ethical & transparent culture in research, clinical care, and teaching.

- I am a member of the Board of Directors for Shire plc.
- I am a member of the Scientific Advisory Boards for Portola Pharmaceuticals and Catalyst Biosciences.
- I benefit from license/patent royalty payments to Boston Children's Hospital (VWF) and the University of Michigan (ADAMTS13).

Learning Objectives

UNDERSTAND:

- The basic anatomy of the human **genome** [eg. 3×10^9 bp (haploid genome); 1-2% coding sequence (~20,000 genes); types and extent of DNA sequence variation].
- **Recombination** and how it allows genes to be mapped
- Genetic data for a pedigree, assigning **phase**, defining **haplotypes**
- **Linkage**: Distinction between a **linked marker** and the disease causing mutation itself
- **Linkage disequilibrium** and **haplotype blocks**
- **Genome wide association studies (GWAS)** to identify gene variants contributing to **complex diseases/traits**
- The implications of **GWAS** findings for clinical care and “**Personalized Medicine**”
- The implications of “**Next-Gen**” **sequencing** for future clinical medicine

DNA Sequence Variation

- **DNA Sequence Variation:**
 - Human to human: ~0.1% (1:1000 bp)
 - Human genome = 3×10^9 bp X 0.1% = $\sim 3 \times 10^6$ DNA common variants
 - Human to chimp: ~1-2%
 - More common in “junk” DNA: introns, intergenic regions
- **poly·mor·phism**
Pronunciation: "päl-i-'mor-'fiz-&m
Function: *noun*
: the quality or state of existing in or assuming different forms: as a **(1)** : existence of a species in several forms independent of the variations of sex **(2)** : existence of a gene in several allelic forms **(3)** : existence of a molecule (as an enzyme) in several forms in a single species

Polymorphisms and Mutations

- Genetic polymorphism:
 - Common variation in the population:
 - Phenotype (eye color, height, etc)
 - genotype (DNA sequence polymorphism)
 - Frequency of minor allele(s) $\geq 1\%$
- DNA (and amino acid) sequence variation:
 - Most common allele ≤ 0.99 = polymorphism
(minor allele(s) $\geq 1\%$)
 - Variant alleles < 0.01 = rare variant
- Mutation-- any change in DNA sequence
 - Silent vs. amino acid substitution vs. other
 - neutral vs. disease-causing
 - 1×10^{-8} /bp/generation (~ 70 new mutations/individual)
- balanced polymorphism= disease + polymorphism
- Common but incorrect usage:
 - “mutation vs. polymorphism”


All DNA sequence variation arises via mutation of an ancestral sequence


	< 1%	≥ 1%
“Normal”	Rare variant or “private” polymorphism	polymorphism
“Disease”	Disease mutation	<i>Example: Factor V Leiden (thrombosis) 5% allele frequency</i>

Common but incorrect usage:


“a disease-causing mutation” **OR** *“a polymorphism”*


*Heteromorphism
of chromosome 1
(one copy)*





*2 normal copies
of chromosome 1*

B.




Key Concepts: Linkage and Recombination



Linkage: A/a and B/b tend to be inherited together

the A and B loci are linked.


Linkage between Marker A/a and Disease D




© PD-INEL Gelehrter, Collins and Ginsburg: *Principles of Medical Genetics 2E*; Figure 9.3

Marker= A or a
 Disease allele = D
 Normal allele = N

Linkage between NF and RFLP marker






FUNCTIONAL CLONING

POSITIONAL CLONING

HD linked to C allele: Two recombinant s (III13, IV1)




© PD-INEL Gelehrter, Collins and Ginsburg: *Principles of Medical Genetics 2E*; Figure 9.26

Gusella, et al. A polymorphic DNA marker genetically linked to Huntington's disease. *Nature* 306:234-238, 1983.


The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. *Cell* 72:971-983, 1993.

Textbook: Figure 9.26

Positional Cloning



Positional Cloning





Preconception and Prenatal Carrier Screening *for* Cystic Fibrosis

Clinical and Laboratory Guidelines



The American College of Obstetricians
and Gynecologists
Women's Health Care Physicians





American College of Medical Genetics

Types of DNA Sequence Variation

- RFLP: Restriction Fragment Length Polymorphism
- VNTR: Variable Number of Tandem Repeats
 - or minisatellite
 - ~10-100 bp core unit
- SSR : Simple Sequence Repetition
 - or STR (simple tandem repeat)
 - or microsatellite
 - ~1-5 bp core unit
- SNP: Single Nucleotide Polymorphism
 - Commonly used to also include rare variants
- Insertions or deletions
 - INDEL – small (few nucleotides) insertion or deletion
- Rearrangement (inversion, duplication, complex rearrangement)
- CNV: Copy Number Variation

STR




SNP

Allele 1




Allele 2



- Most are “silent”
- Intragenic
- Promoters and other regulatory sequences
- Introns
- Exons
 - 5' and 3' untranslated regions
 - Coding sequence (~1-2% of genome)

Human Chromosome 4



2010

- 23,653,737 total human entries in dbSNP
<http://www.ncbi.nlm.nih.gov/projects/SNP/>
- Chromosome 4
– 4,311,728 SNPs
- ~1M SNP chip commercially available

15 February 2001

nature

www.nature.com

the human genome

Nuclear fission

Five-dimensional
energy landscapes

Seafloor spreading

The view from under
the Arctic icepack


Career prospects


Sequence creates new
opportunities

naturejobs

genomics special

Genes Identified: Monogenic Diseases





Haploid Human Genome 3×10^9 bp, ~20,000 genes

1 Chromosome
~1300 genes



Single Gene
~1.5 Kb (Globin to
 2×10^6 bp (Dystrophin))



H. Influenzae
~1700 genes

S. Cerevisiae
~6250 genes



D. Melanogaster
~14000 genes

 Andre Karwath (wikipedia)



C. Elegans
~18500 genes

 U.S. Federal Government (wikipedia)

Genomes


- *Complete human genome (~100 individual genomes, 1000 genomes in progress)*
- *Complete genomes of >6500 other species*
- Plants (arabidopsis, oat, soybean, barley, wheat, rice, tomato, corn) ...
- Yeast, fly, worm, human, mouse, rat, zebrafish, mosquito, malaria, ciona ...
- Cow, pig, frog, chimp, gorilla, dog, chicken, cat, bee ...

The Human Genome

23 pairs of chromosomes made of 3 billion base pairs

Extragenic DNA


- Repetitive sequences
- Control regions
- Spacer DNA between genes
- Function mostly unknown



Characteristics of the Human Genome Sequence

- 99% of euchromatin is covered, 2.85 Gb
- Error rate: $\ll 1:100,000$ bp
- <350 unclonable gaps
- All data is freely accessible without restriction
- Humans have fewer genes than expected
 - $\sim 20,000$ from prev. estimates of 100,000)
 - ? human genes make more proteins
- $\sim 1\text{-}2\%$ of genome = coding sequences
- $\sim 1\%$ = highly conserved noncoding sequences


Base Pairs in Genbank



NCBI HomePage - Windows Internet Explorer

http://www.ncbi.nlm.nih.gov/

NCBI HomePage


National Center for Biotechnology Information
 National Library of Medicine National Institutes of Health

[PubMed](#) [All Databases](#) [BLAST](#) [OMIM](#) [Books](#) [TaxBrowser](#) [Structure](#)

Search for

SITE MAP
 Alphabetical List
 Resource Guide

About NCBI
 An introduction to NCBI

GenBank
 Sequence submission support and software

Literature databases
 PubMed, OMIM, Books, and PubMed Central

Molecular databases
 Sequences, structures, and taxonomy

Genomic biology

▶ What does NCBI do?

Established in 1988 as a national resource for molecular biology information, NCBI creates public databases, conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information - all for the better understanding of molecular processes affecting human health and disease. [More...](#)

New Protein Clusters
 Entrez Protein Clusters database


The new Entrez Protein Clusters database is a collection of Reference Sequence (RefSeq) proteins, from the complete genomes of prokaryotes, plasmids, and organelles, that have been grouped and annotated based on sequence similarity and protein function. Click here to find out more about the [Protein Clusters](#) database.

New dbGaP
 NCBI's dbGaP Genome Wide Association Database


Hot Spots

- ▶ Assembly Archive
- ▶ Clusters of orthologous groups
- ▶ Coffee Break, Genes & Disease, NCBI Handbook
- ▶ Electronic PCR
- ▶ Entrez Home
- ▶ Entrez Tools
- ▶ Gene expression omnibus (GEO)
- ▶ Human genome resources
- ▶ Influenza Virus Resource
- ▶ Map Viewer

http://genome.ucsc.edu




Key Concepts: Linkage and Recombination



Linkage: A/a and B/b tend to be inherited together


the A and B loci are linked.

The HLA (MHC) Locus




Assigning Phase


A.



B.



Linkage Disequilibrium



These three SNPs could theoretically occur in 8 different haplotypes

...C...A...A...

...C...A...G...

...C...C...A...

...C...C...G...

...T...A...A...

...T...A...G...

...T...C...A...

...T...C...G...

But in practice,
only two are observed

...C...A...A...

...C...A...G...

...C...C...A...

...C...C...G...

...T...A...A...

...T...A...G...

...T...C...A...

...T...C...G...

These three variants are said to be in linkage disequilibrium

...C...A...A...

...C...A...G...

...C...C...A...

...C...C...G...

...T...A...A...


...T...A...G...

...T...C...A...

...T...C...G...

Founder Effect

A high frequency of a specific gene mutation in a population founded by a small ancestral group




Original
population


Marked population
decrease, migration,
or isolation

Generations
later


~ 20 kb




Affected



Unaffected





© PD-INEL

Hb S only occurs on 4 haplotypes...only occurred 4 times in history

Could we use this approach to find human disease genes (identify specific haplotypes present more often in patients than in controls)?

Next Generation (NexGen) Sequencing Technologies

Searching for Cheaper Genome Sequencers

Company	Format	Read Length (bases)	Expected Throughput MB (million bases)/day
454 Life Sciences	Parallel bead array	100	96
Agencourt Bioscience	Sequencing by ligation	50	200
Applied Biosystems	Capillary electrophoresis	1000	3-4
Microchip Biotechnologies	Parallel bead array	850-1000	7
NimbleGen Systems	Map and survey microarray	30	100
Solexa	Parallel microchip	35	500
LI-COR	Electronic microchip	20,000	14,000
Network Biosystems	Biochip	800+	5
VisiGen Biotechnologies	Single molecule array	NA	1000

Generation next. Companies racing for the \$1000 genome sequence strive simultaneously for low cost, high accuracy, the ability to read long stretches of DNA, and high throughput.

Learning Objectives

UNDERSTAND:

- The basic anatomy of the human **genome** [eg. 3×10^9 bp (haploid genome); 1-2% coding sequence (~20,000 genes); types and extent of DNA sequence variation].
- **Recombination** and how it allows genes to be mapped
- Genetic data for a pedigree, assigning **phase**, defining **haplotypes**
- **Linkage**: Distinction between a **linked marker** and the disease causing mutation itself
- **Linkage disequilibrium** and **haplotype blocks**
- **Genome wide association studies (GWAS)** to identify gene variants contributing to **complex diseases/traits**
- The implications of **GWAS** findings for clinical care and “**Personalized Medicine**”
- The implications of “**Next-Gen**” **sequencing** for future clinical medicine

Additional Source Information

for more information see: <http://open.umich.edu/wiki/AttributionPolicy>

Slide 22: Source Undetermined; Andre Karwath (wikipedia); U.S. Federal Government (wikimedia)

Slide 24: Source Undetermined

Slide 26: National Center for Biotechnology, <http://www.ncbi.nlm.nih.gov/>

Slide 27: Gelehrter, Collins and Ginsburg: Principles of Medical Genetics 2E

Slide 28: University Of California Santa Cruz, <http://genome.ucsc.edu>

Slide 29: Levy, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:488-494, 2001.

Slide 30: University Of California Santa Cruz, <http://genome.ucsc.edu>

Slide 31: National Center for Biotechnology, <http://www.ncbi.nlm.nih.gov/Omim/mimstats.html>

Slide 41: Regents of The University of Michigan

Slide 42: Regents of The University of Michigan

Slide 46: Gelehrter, Collins and Ginsburg: *Principles of Medical Genetics 2E*, Figure 10.3

Slide 47: Ricardipus, flickr, <http://creativecommons.org/licenses/by-sa/2.0/deed.en>